RED BANK, NEW JERSEY / ACCESS Newswire / August 13, 2025

RED BANK, NEW JERSEY / ACCESS Newswire / August 13, 2025 / Tharimmune, Inc. (Nasdaq:THAR) (“Tharimmune” or the “Company”), a clinical-stage biotechnology company dedicated to developing innovative therapeutic candidates for inflammation, immunology, and critical unmet medical needs, today announced a significant expansion of its intellectual property portfolio for TH-104, its novel transmucosal film. The new patents, recently granted […]

RED BANK, NJ / ACCESS Newswire / August 5, 2025

RED BANK, NJ / ACCESS Newswire / August 5, 2025 / Tharimmune, Inc. (NASDAQ:THAR), (“Tharimmune” or the “Company), a clinical-stage biotechnology company dedicated to developing innovative therapeutic candidates for inflammation, immunology, and critical unmet medical needs, today proudly announced the appointment of Nancy Davis, a globally recognized philanthropist, tenacious advocate, and the visionary founder of the renowned Race to […]

RED BANK, NJ / ACCESS Newswire / August 4, 2025

-Company closes approximately $5.47 million in equity financing in 2Q/3Q25 -TH104 potentially fills a critical National Security Need against Weaponized Fentanyl –TH023 may fulfill the promise of delivering a safe and effective oral antibody medication against inflammation -Company Strengthens Operational Leadership, Corporate Governance and Accounting RED BANK, NJ / ACCESS Newswire / August 4, 2025 / Tharimmune, Inc. […]